Solara Active Pharma Sciences Limited (SOLARA)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 21 July 2026

₹570.15 ↓ 15.49% (1Y)

🎯 Key Takeaways

Solara Active Pharma Sciences Limited is in a critical turnaround phase, transitioning from sustained losses in prior quarters to emerging profitability in recent periods. The company has demonstrated sequential improvement in operational performance and margin expansion, particularly in Q3FY25, signaling potential stabilization after years of losses.
Revenue declined 13.4% QoQ to ₹300 in Q3FY25.
⚠️ Revenue volatility remains a concern, with sequential declines observed despite margin improvements, raising questions about sustainable demand.

Market Cap

₹2,098

P/E Ratio

-8.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About SOLARA 📊 Interactive Charts

📖 The Story

Solara Active Pharma Sciences Limited is in a critical turnaround phase, transitioning from sustained losses in prior quarters to emerging profitability in recent periods. The company has demonstrated sequential improvement in operational performance and margin expansion, particularly in Q3FY25, signaling potential stabilization after years of losses. However, profitability remains volatile, with significant swings in net profit and EPS over the past two years, indicating execution risks and uncertain demand dynamics in the pharmaceutical formulation space.

📰 What's Happening

Management has recently scheduled a conference call for Q1FY27 results on July 23, 2026, to discuss performance and outlook, marking the first earnings discussion following the company's return to profitability in Q3FY25. The company also issued a final reminder for call money payments related to its rights issue, requiring shareholder payments by July 27, 2026, to avoid forfeiture. Additionally, shares unclaimed for seven consecutive years, including 2018-19, will be transferred to the Investor Education and Protection Fund (IEPF) by September 10, 2026, potentially reducing dormant shareholder liabilities. The company has also seen credit rating upgrades from Crisil, reflecting improved financial stability, and allotted shares under its ESOP 2024, increasing paid-up capital marginally.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	381	352	425	249	299	363	347	300
Operating Profit	53	21	34	-224	-111	42	62	59
OPM %	12.8%	5.4%	8.8%	-65.0%	3.3%	11.5%	17.7%	19.2%
Net Profit	4	-19	-17	-275	-255	-13	8	8
EPS	₹1.05	₹-5.43	₹-4.77	₹-76.49	₹-70.93	₹-3.50	₹2.54	₹2.03

The company's financial trajectory shows a clear inflection point: after posting losses in Q4FY24 and Q3FY24, Solara achieved profitability in Q3FY25 with a net profit of ₹8 crores and EPS of ₹2.03, reversing prior losses of ₹255 crores and ₹-70.93 EPS in Q4FY24. This improvement is supported by margin expansion to 19.2% in Q3FY25 from 11.5% in Q1FY25, suggesting better cost control or pricing power. However, revenue declined sequentially from ₹363 crores in Q1FY25 to ₹300 crores in Q3FY25, indicating possible softness in demand or pricing pressure. The company remains sensitive to quarterly volatility, with operating profit swinging from a loss of ₹111 crores in Q4FY24 to a gain of ₹62 crores in Q2FY25.

🔮 Management Outlook & What's Next

Management has not yet provided explicit forward guidance in the reviewed filings, but the scheduled conference call for Q1FY27 results on July 23, 2026, presents a key opportunity to hear direct commentary on future performance. The company has previously emphasized compliance with regulatory norms, capital structure management, and operational efficiency as part of its strategic focus. Investors will likely watch for updates on order book strength, segment performance, and any guidance on margin sustainability or revenue growth trends.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Revenue volatility remains a concern, with sequential declines observed despite margin improvements, raising questions about sustainable demand. 2. Profitability is still fragile, as evidenced by losses in Q4FY24 and Q1FY25, suggesting that current gains may not be linear or durable without structural demand recovery. 3. The company's reliance on regulatory compliance events (e.g., trading window closures, IEPF transfers) highlights governance complexity and potential reputational risks. 4. High historical losses and negative net net worth in prior periods pose ongoing financial stability concerns, especially if operating performance stalls.

📋 Recent Filings

🧠 Analyst's Read

Solara Active Pharma Sciences is showing early signs of a potential turnaround, supported by margin expansion and return to profitability, but the trajectory remains uncertain due to revenue softness and historical volatility. Investors should monitor the upcoming Q1FY27 earnings call for clarity on demand trends, margin sustainability, and management's outlook on growth drivers. The company's ability to maintain profitability amid pricing pressures in the generic pharmaceutical market will be critical to watch in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SOLARA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-21.

📡 Get AI alerts when SOLARA files new disclosures

Track SOLARA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SOLARA — Free

Free account · 2 AI queries/day